Although compounds for treating or ameliorating malignant diseases have been proposed, patients had to endure a large burden since many of such compounds could not be orally ingested. Mangiferin has an effect of ameliorating malignant diseases through oral ingestion. However, such effect is minor and realistically it was not easy to ingest mangiferin. Further, in order to develop more effective pharmaceutical agents and the like for treating malignant diseases, it has been considered constantly necessary to obtain new or improved forms of an existing medical agent for inhibiting kinases such as NIK. Compounds represented by formula (1), formula (2), formula (3), formula (4), formula (5), formula (6), formula (7), formula (8), formula (9), formula (10), formula (11), and formula (12) have an effect of ameliorating malignant diseases through oral ingestion, and can exhibit said effect with an amount less than that for mangiferin.

The present invention relates to a compound represented by the general formula (A), a base generator comprising the compound, a base-reactive composition which comprises the base generator and a base-reactive compound, as well as a method for generating a base, etc. ##STR00001##

The present invention relates to a compound represented by the general formula (A), a base generator comprising the compound, a base-reactive composition which comprises the base generator and a base-reactive compound, as well as a method for generating a base, etc. ##STR00001##

The present invention relates to compounds of general formula (I) ##STR00001## wherein R.sup.1-R.sup.8 take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of cancer.

The present invention relates to compounds of general formula (I) ##STR00001## wherein R.sup.1-R.sup.8 take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of cancer.

Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.

Disclosed are tricyclic heterocyclic compounds having kinase inhibitory activity, pharmaceutical compositions and kits comprising the compounds, and use of the compounds in the treatment of or in medicaments for the treatment of various diseases and conditions. In particular, disclosed are tricyclic heterocyclic compounds of the formula (I) having CSF-1R (c-FMS kinase) inhibitory activity and their use in the treatment of various diseases and conditions, such as those mediated by CSF-1R, including proliferative or neoplastic diseases and conditions, including cancers, and bone, inflammatory, and autoimmune diseases and conditions.

Provided is an electronic apparatus including: a substrate; a pixel defined layer defining a plurality of pixel areas and a plurality of non-pixel areas on the substrate; a plurality of light-emitting diodes arranged on the plurality of the pixel areas; and a thin film encapsulation portion including an organic film and sealing the pixel defined layer, or the plurality of the light-emitting diodes and the pixel defined layer, wherein the organic film includes a curable material of a composition for forming an organic film, the composition including at least one UV absorber.

Provided is an electronic apparatus including: a substrate; a pixel defined layer defining a plurality of pixel areas and a plurality of non-pixel areas on the substrate; a plurality of light-emitting diodes arranged on the plurality of the pixel areas; and a thin film encapsulation portion including an organic film and sealing the pixel defined layer, or the plurality of the light-emitting diodes and the pixel defined layer, wherein the organic film includes a curable material of a composition for forming an organic film, the composition including at least one UV absorber.

In alternative embodiments, provided are processes comprising the continuous isolation and purification of cannabinoids and further isomerization of the purified cannabidiol to .sup.8tetrahydrocannabinol (.sup.8THC) and .sup.9tetrahydrocannabinol (.sup.9THC). In alternative embodiments, provided are processes for converting 8-THC into .sup.9-THC. In alternative embodiments, provided are processes for the industrial scale continuous isolation and purification of cannabinoids and further isomerization of the purified cannabidiol to .sup.9-THC.